📢 New preprint from BioFINDER, led by @karlssonlinda1.bsky.social! We trained a deep learning model to generate synthetic tau-PET 3D scans from more accessible data: structural MRI, plasma p-tau217, and age. medrxiv.org/content/10.6...
@biofinder.bsky.social
New paper in Neurology! We investigated whether future AD dementia can be predicted in individuals with subjective cognitive decline. We found that plasma p-tau217, cognitive testing, and APOE ε4 status accurately identify those at highest risk. neurology.org/doi/pdf/10.1...
The Role of Clinical, Plasma, and Imaging Biomarkers in Assessing Future Dementia Risk in Individuals With Subjective Cognitive Decline | Neurology
Background and ObjectivesSubjective cognitive decline (SCD) is a well-recognized risk state for developing mild cognitive impairment (MCI) and dementia. Optimal risk stratification for early intervent...
neurology.org
New publication in JAMA Neurology! 🧠 In this study, led by @gsalvado.bsky.social, we developed and validated a plasma-based biological staging model for Alzheimer’s disease using two blood biomarkers: %p-tau217 and eMTBR-tau243. jamanetwork.com/journals/jam...
Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer Disease
This longitudinal study develops and validates a blood plasma–based biological staging model for Alzheimer disease that closely mirrors an amyloid and tau positron emission tomography–based staging sy...
jamanetwork.com
New paper in Nature Aging led by PhD student Lina Lu! We mapped how APOE ε4 and APOE ε2 shape molecular changes in blood and cerebrospinal fluid across Alzheimer’s disease. www.nature.com/articles/s43...
Proteomic signatures of the APOE ε4 and APOE ε2 genetic variants and Alzheimer’s disease - Nature Aging
Apolipoprotein E (APOE) is the strongest genetic influence in Alzheimer’s disease (AD). Compared to the most frequent allele, ε3, the ε4 allele increases AD risk, and the ε2 allele is protective. Here...
nature.com
New paper in Nature Communications! We mapped trajectories of multiple tau species in plasma & CSF across the AD continuum. Different tau species change at distinct stages: %p-tau217 earliest, MTBR-tau243 later, highlighting stage-specific biology. www.nature.com/articles/s41...
Trajectories of plasma and CSF MTBR-tau243 and phosphorylated-tau species across the Alzheimer’s disease continuum - Nature Communications
Plasma and CSF p-tau biomarkers show similar dynamics across Alzheimer’s disease progression, though plasma %p-tau217 and eMTBR-tau243 show less ceiling effect than CSF. Combining %ptau217, %p-tau205,...
nature.com
New publication alert! Are patients seen in primary care eligible for amyloid-targeting therapies (ATT) for treatment of Alzheimer’s disease? 🧠We evaluated ATT eligibility among patients with cognitive symptoms in primary care in southern Sweden.
New publication out in Brain! 📢We developed a data-driven multimodal biomarker framework to characterize a memory clinic cohort based on the presence, extent, and sequence of common pathologies. This framework may support diagnosis and trial selection. 🔗https://doi.org/10.1093/brain/awaf411
New publication out in Brain! 📢 We found that reference proteins Aβ40 and np-tau consistently helped already high-performing fluid biomarkers (e.g., MTBR-tau243 and p-tau variants) to more reliably represent brain Aβ and tau pathology measured by PET. 🔗 academic.oup.com/brain/advanc...
Validate User
academic.oup.com
New BioFINDER preprint! We formalise the Aβ–tau–neurodegeneration (ATN) framework into a mechanism-based model of Alzheimer’s disease, enabling us to simulate longitudinal imaging biomarkers and study how disease processes evolve and interact across the AD continuum. www.biorxiv.org/content/10.6...
New paper out in EMBO Mol Med! We use machine learning to predict Aβ-PET burden from fluid biomarkers. www.embopress.org/doi/full/10.... Key findings: - Performance R² = 0.79 - CSF Aβ42/Aβ40 most predictive of Aβ plaque presence - Plasma p-tau217 best for tracking increasing amyloid plaque burden
Prediction of continuous amyloid positron emission tomography with fluid measures of phosphorylated tau and β-amyloid | EMBO Molecular Medicine
imageimageMachine-learning models using CSF and plasma biomarkers accurately predicted quantitative Aβ-PET burden. Distinct contributions of soluble Aβ42/Aβ40 and plasma P-tau217 reveal their role in ...
embopress.org
🚨Paper Out! Systematic Review & Meta-analysis of ALS Fluid Biomarkers 🧵Key findings: • NfL leads for both diagnosis (AUC 0.81–0.92) & prognosis (HR 2.8–4.3) • CSF chitinases, p-tau/t-tau: moderate values • Marked heterogeneity onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com
🚨New publication in Alzheimer's & Dementia! In this perspective paper, we discuss whether Aβ blood biomarkers can replace the accepted reference standard, Aβ-PET, for assessing Aβ burden. 🔗Full paper: alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
Complementary utility of plasma biomarkers and Aβ‐PET for diagnosis, risk‐stratification, and treatment monitoring in Alzheimer's disease
With the rapid development of blood biomarkers (BBMs) related to amyloid-β (Aβ) pathology in Alzheimer's disease (AD), the question arises whether these can replace the accepted reference standard, ...
alz-journals.onlinelibrary.wiley.com
🚨New publication in Brain Communications! In this study led by Atul Kumar, we show that microglial cells play a key role in Alzheimer's disease, particularly in regulating changes in soluble tau, based on cell-type-specific genetic evidence. 🔗Full paper: academic.oup.com/braincomms/a...
Cell-weighted polygenic risk scores are associated with β-amyloid and tau biomarkers in Alzheimer’s disease
Kumar et al. report distinct cellular effects on measures of β-amyloid and tau. Importantly, they also found cell-level genetic evidence for a role for mic
academic.oup.com
🚨Paper alert🚨 New publication in JAMA Neurology led by @gsalvado.bsky.social. In a multicentric study, we examined the clinical utility to assess preclinical #Alzheimer’s disease in cognitively unimpaired individuals. jamanetwork.com/journals/jam... A 🧵...
Plasma P-Tau217 to Identify Preclinical AD
This cohort study evaluates the use of plasma phosphorylated tau 217 in identifying preclinical Alzheimer disease in individuals with amyloid β pathology.
jamanetwork.com
🚨New publication in Nature Medicine! In this study, we demonstrate that a brief, self-administered cognitive test battery can reliably identify individuals with cognitive impairment in a primary care setting. More details: linkedin.com/feed/update/... Full paper: www.nature.com/articles/s41...
Primary care detection of Alzheimer’s disease using a self-administered digital cognitive test and blood biomarkers - Nature Medicine | The Swedish BioFINDER study
New publication in Nature Medicine! In this study, led by PhD students Pontus Tideman and Linda Karlsson, we demonstrate that a brief, self-administered cognitive test battery can reliably identify ...
linkedin.com
🚨New paper alert! Our study led by @teanijarv.bsky.social investigated why some individuals with Alzheimer’s disease (AD) develop hemispheric asymmetry in tau pathology and what drives this phenomenon. Out now in Nature Communications! 🔗Full article: doi.org/10.1038/s414... A thread🧵👇
Hemispheric asymmetry of tau pathology is related to asymmetric amyloid deposition in Alzheimer’s Disease - Nature Communications
Asymmetrical distribution of tau pathology in Alzheimer’s disease is linked to asymmetrical amyloid-beta deposition, not reduced brain connectivity, suggesting regional vulnerability plays a key role ...
doi.org
🚨New publication in Nature Aging🚨 Co-led between Laia Montoliu-Gaya and @gsalvado.bsky.social. We measured several tau peptides in blood and assess their different relationships with Alzheimer’s disease stages. nature.com/articles/s43... 🧵
Plasma tau biomarkers for biological staging of Alzheimer’s disease - Nature Aging
Montoliu-Gaya, Salvadó et al. develop a blood-based model using tau biomarkers measured in a single analysis enabling biological staging of Alzheimer’s disease to support the diagnosis, prognosis and ...
nature.com
🚨New paper alert! This study led by Sophie Mastenbroek aims to make detection of α-synuclein pathology in the brain more time- and cost-effective. Out now in Nature Communications! 🔗 Full article: nature.com/articles/s41... A thread🧵👇
Two-step detection of Lewy body pathology via smell-function testing and CSF α-synuclein seed amplification
Nature Communications - CSF α-synuclein seed amplification assays detect Lewy body pathology accurately but are invasive and costly. Here, the authors show that a two-step workflow using...
nature.com
🚨This study led by @anikawuestefeld.bsky.social aims to provide a more granular understanding of how tau pathology leads to specific cognitive decline in Alzheimer's disease. 🧠 Out now in Alzheimer’s & Dementia! Read it here: doi.org/10.1002/alz.... 🧵👇
Tau, atrophy, and domain‐specific cognitive impairment in typical Alzheimer's disease
INTRODUCTION A granular understanding of the mechanisms linking tau pathology to cognitive decline in Alzheimer's disease is crucial. We investigate mediating effects of medial temporal lobe (MTL) a...
doi.org
New manuscript alert! Are plasma biomarkers🩸 predictive of Alzheimer’s disease progression in Down Syndrome (DS)? Our new study in collaboration with the ABC-DS consortium has now been published in @thelancetneuro.bsky.social: www.thelancet.com/journals/lan...
Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers: a longitudinal cohort study
Baseline and longitudinal plasma p-tau217 were associated with subsequent decline in global cognition, progression to dementia, and increased tau burden, whereas baseline p-tau217 and GFAP were associ...
thelancet.com
🚨Exciting new preprint from a great collaboration between our group and the talented PhD student @jorittmo.bsky.social from @jwvogel.bsky.social's group! They investigate how the 🧠 reorganises in the context of age and AD. Dive into the details here 🧵👇
Jonathan Rittmo@jorittmo.bsky.social · last yr.How does the brain reorganize in the context of age and AD? Are functional changes in age and AD similar? Are these changes dynamic across the age/AD spectrum? We unpack these questions in a sample of N=973 with AD biomarkers Preprint: tinyurl.com/ymv8s7h8 ⬇️🧵 1/
🚨New paper in Alzheimer's & Dementia! We investigate whether p-tau immuno-assays selectively quantifying low-molecular-weight (LMW) tau (CNS) are more specific for tau changes in AD vs ALS than assays not differentiating between LMW and high-MW (PNS) tau👇https://pubmed.ncbi.nlm.nih.gov/40289884/
🧠Exciting new findings from a great collaboration between the BioFINDER study and the talented @xiaoyucaly.bsky.social from @jwvogel.bsky.social group!! In their preprint, they show that tau presence and tau load are guided by unique brain mechanisms. Dive into the details here 👇
Yu Xiao (肖燏)@xiaoyucaly.bsky.social · last yr.🧠New preprint! What drives tau, the pathological protein in AD, to spread? We found that WHERE tau appears and HOW MUCH accumulates are governed by different mechanisms. Check it out: www.biorxiv.org/content/10.1... #MedSky #neuroskyence #neurosky #alzsky #compneuro #MRI #neuroimaging #neurology
‼️New preprint! We are happy to share our latest work led by @teanijarv.bsky.social investigating why tau pathology in AD often accumulates more in one hemisphere of the brain than the other. Check out 🔗https://biorxiv.org/content/10.1101/2025.04.15.648728v1 or dive into the details below👇
🚨New paper alert! Research from our group and collaborators at The University of Melbourne shows increased speed of neuronal aging in schizophrenia- the same phenomena was not seen in bipolar disorder. 📖Read more here: theconversation.com/brains-of-pe...
Brains of people with schizophrenia may age faster – how our research adds to the evidence
Study suggests accelerated brain ageing is a factor in the development of schizophrenia – and can be measured using a simple blood test.
theconversation.com
New manuscript alert! Can blood-based biomarkers measured on a fully automated platform accurately identify Alzheimer’s disease (AD) pathology?🩸 Our new multi-cohort study has now been published in @naturemedicine.bsky.social: nature.com/articles/s41.... A thread🧵
Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform - Nature Medicine
Among 1,767 patients in 5 centers, a fully automated blood test showed high accuracy for Alzheimer’s pathology in secondary and primary care using a predefined cutoff.
nature.com
Guten Morgen! 👋 Start the day with more presentations from our group.
We hope you had a great first day! Continuing #ADPD2025 with a forum discussion on blood-based biomarkers by Oskar Hansson.
Don’t miss out on our #ADPD2025 on-demand presentations about brain reserve in frontotemporal dementia, a sensitive visual read algorithm for assessing tau PET images, and the correlation between biomarkers and and [18F] dopa-pet!
